Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li><keyword id="20078817" type="General" weightage="20" keywordseo="Susan-Wojcicki" source="keywords">Susan Wojcicki</keyword>, the former CEO of YouTube, died at 56 from <keyword id="21401827" type="General" weightage="20" keywordseo="non-small-cell-lung-cancer" source="keywords">non-small cell lung cancer</keyword> (<keyword id="20036342" type="General" weightage="20" keywordseo="NSCLC" source="keywords">NSCLC</keyword>).</li><li>NSCLC accounts for 85% of all <keyword id="20557921" type="General" weightage="20" keywordseo="lung-cancer" source="keywords">lung cancer</keyword> cases, many of which are diagnosed late.</li></ul>Susan Wojcicki, the former CEO of YouTube, <a target="_blank" href="https://www.businessinsider.com/susan-wojcicki-dead-2024-8">died from lung cancer on Friday</a>. She was 56.<br /><br />In a <a target="_blank" href="https://www.facebook.com/dtroper/posts/10162253810115312?ref=embed_post">Facebook post</a>, her husband, Dennis Troper, said that Wojcicki died "after 2 years of living with non small cell lung cancer."<br /><br />Non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of 230,000 diagnosed lung cancer cases each year, according to <a target="_blank" href="https://www.yalemedicine.org/conditions/non-small-cell-lung-cancer">Yale Medicine</a>.<br /><br /><h2><strong>Non-small cell lung cancer is often diagnosed late</strong></h2>There are two types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In NSCLC, the cancer cells are larger, according to <a target="_blank" href="https://my.clevelandclinic.org/health/diseases/6203-non-small-cell-lung-cancer">Cleveland Clinic</a>.<br /><br />Symptoms can include a <a target="_blank" href="https://www.businessinsider.com/woman-cough-was-stage-4-lung-cancer-2022-8">persistent cough</a>, coughing up blood, chest pain, wheezing, fatigue, appetite loss, and face swelling.<br /><br />Because some non-small cell lung cancer symptoms can resemble other illnesses like <a target="_blank" href="https://www.clinicbyclevelandclinic.com/blog/how-often-is-lung-cancer-misdiagnosed/">bronchitis</a>, about 80% of cases are diagnosed at later stages, making it harder to treat once the cancer has <a target="_blank" href="https://www.businessinsider.com/woman-shoulder-pain-lung-cancer-spread-symptoms-2022-9">spread to other parts of the body</a>, according to Yale Medicine.<br /><br /><h2><strong>Smoking is the biggest risk factor, even if you quit</strong></h2>According to Cleveland Clinic, the biggest risk factor for NSCLC is smoking. Other risks include exposure to asbestos, metal and mineral dust, air pollution, radon, and radiation therapy. Some infections and diseases, like HIV/AIDS and Chronic obstructive pulmonary disease, also increase risks.<br /><br />Most guidelines recommend <a href="https://emedicine.medscape.com/article/2241676-overview" target="_blank">annual NSCLC screenings for people ages 50 to 80</a> who have <a href="https://shouldiscreen.com/English/pack-year-calculator#:~:text=If%20you%20have%20smoked%20a,you%20have%2020%20pack%2Dyears." target="_blank">20-pack year smoking history</a> — that is, who smoked at least a pack of cigarettes a day for 20 years or two packs a day for 10 years — and have either quit or continued to smoke within the last 15 years.<br /><br /><em>Correction: August 12, 2024 — An earlier version of this story misrepresented the definition of "pack year." A 20 pack-year is calculated by the packs of cigarettes smoked per day over a set of years, not smoking 20 packs of cigarettes a year.</em><br />

Susan Wojcicki, YouTube CEO, died at 56 from a type of lung cancer that is often diagnosed late

<ul class="summary-list"><li><strong><keyword id="11094896" type="UNKNOWN" weightage="60" keywordseo="novocure">NovoCure</keyword> Limited spiked as much as 65% on Tuesday to its highest since it listed in 2015.</strong></li><li><strong> The surge came amid the company's update on its phase three trial for the treatment of non-small cell <keyword id="33225" type="ORGANIZATION" weightage="60" keywordseo="lung-cancer">lung cancer</keyword>.</strong></li><li><strong>An independent committee gave it the green light to recruit more patients for its trial.</strong></li></ul><p>NovoCure Limited spiked as much as 65% on Tuesday to its highest since it listed in 2015 after the global oncology company gave an <a href="https://www.businesswire.com/news/home/20210413005428/en/Novocure-Announces-Update-on-Phase-3-Pivotal-LUNAR-Trial-of-Tumor-Treating-Fields-in-Non-Small-Cell-Lung-Cancer">update on its phase three trial</a> for the treatment of non-small cell lung cancer (NSCLC).</p><p>The Jersey-based company on Tuesday announced that an independent data monitoring committee gave it the green light to recruit more patients for its phase three Lunar trial of tumor treating fields in stage four NSCLC.</p><p>The committee also accelerated its late-stage study in non-small cell lung cancer.</p><p>Novocure initially needed 534 patients with 18 months of follow-up for its study. The board now recommended a reduced sample size of 276 patients with 12 months follow-up, which it said will be sufficient. No other changes to the design of the trial were recommended.</p><p>The goal of the trial is to help patients survive when treated with TTFields and immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone.</p><p>NovoCure has notified the US Food and Drug Administration.</p><p>"The completion of the Lunar interim analysis is an important milestone for Novocure," said Asaf Danziger, NovoCure's CEO. "Pending regulatory approval, the recommended protocol adjustments could accelerate trial completion by more than a year. We look forward to sharing final data from the Lunar trial as quickly as possible."</p><p>Worldwide, lung cancer is the most common cause of cancer-related death, with NSCLC accounting for 85% of all lung cancers, the company said. Approximately 193,000 patients are diagnosed with NSCLC in the US each year.</p><p>NovoCure has operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. It also has global offices in Germany, Switzerland, Japan, and Israel. </p>

NovoCure surges 65% to all-time high on upbeat review of its lung cancer treatment trial

<p><span class="KonaFilter image-container display-table float_right"><span><span data-post-image="" class="image on-image"></span><p></p></span></span>There's a new lung cancer vaccine in town.</p>
<p>Well, almost.</p>
<p>For now, it's still in Cuba, where it's already <a href="http://www.cnn.com/2009/HEALTH/02/19/cuba.cancer.vaccine/index.html?iref=24hours">being given out for free as part of a course of </a><a href="http://www.cnn.com/2009/HEALTH/02/19/cuba.cancer.vaccine/index.html?iref=24hours">routine treatment for people with advanced lung cancer</a>. But it's on track to show up on American shores soon, possibly within a year, <a href="http://www.wired.com/2015/05/cimavax-roswell-park-cancer-institute/">according to Wired</a>.</p>
<p>The vaccine, called CimaVax, is the result of a collaboration between US and Cuban research centers. The software for the effort is being provided by Manhattan-based tech company Infor.</p>
<p>Last month, the New York-based Roswell Park Cancer Institute announced it would work with Havana's Center for Molecular Immunology to bring the vaccine to the US during a meeting between New York Governor Andrew Cuomo, Cuban First Vice President Miguel Diaz-Canel, and several Cuban trade officials, <a href="http://www.bloomberg.com/politics/articles/2015-04-20/cuomo-says-cuba-visit-will-pressure-congress-to-lift-embargo">Bloomberg reports</a>. That meeting made Cuomo the first US governor to visit Cuba since President Obama eased travel restrictions to the country.</p>
<p>CimaVax helps treat lung cancer's symptoms - which can include chest pain, hoarseness, and intense fatigue - and could help prevent the disease from recurring, or coming back, in people who have gone a period of time with no symptoms, Roswell Park Cancer Institute Director Candace Johnson&#xa0;<a href="http://wivb.com/2015/04/21/roswell-park-cancer-center-pens-deal-with-cuban-center/" target="_blank">told WIVB News 4</a>.</p>
<p>Johnson hopes to get approval for testing CimaVax in the US within 6-8 months and to start clinical trials of the drug within a year, <a href="http://www.wired.com/2015/05/cimavax-roswell-park-cancer-institute/">she told Wired</a>.</p>
<h2>Why Cuba?</h2>
<p>Cuba leads the world with its high concentration of health workers. <a href="http://www.who.int/whosis/whostat2007/en/">They have around 600 doctors and nurses for every 100,000 citizens</a>; the US has about 250 doctors and nurses for every 100,000 citizens.</p>
<p>And Cuba puts them to work. The country has a floating squadron of <a href="http://www.theguardian.com/global-development/2014/oct/22/cuban-doctors-west-africa-fight-ebola">50,000</a> doctors and nurses on the ground in developing countries led by the government. In the US, that program's closest parallel is Doctors Without Borders, but that program is run by a nonprofit organization.</p>
<p>Plus, despite <a href="http://www.businessinsider.com/life-expectancy-vs-healthcare-spending-2014-3">spending far less on healthcare per person than the US does</a>, Cuba has <a href="http://ucatlas.ucsc.edu/spend.php">nearly the same average life expectancy</a>.</p>
<p><a href="http://www.paho.org/saludenlasamericas/index.php?option=com_docman&amp;task=doc_view&amp;gid=125&amp;Itemid=">Lung cancer is the leading cause of death in 12 of Cuba's 15 provinces</a>. In 2011, nearly three decades after researchers at the Center for Molecular Immunology began working on the drug, the Cuban government began making it available to its citizens at no cost, <a href="http://www.wired.com/2015/05/cimavax-roswell-park-cancer-institute/">Wired reports</a>.</p>
<p>A <a href="http://www.ncbi.nlm.nih.gov/pubmed/20387330">2010 review</a> of phase two trials of CimaVax conducted in Cuba between 1995 and 2005 found that patients with lung cancer who got Cimavax lived an average of 4-6 months longer than those who got traditional treatments. These trials occurred in patients with <a href="http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer">non-small cell lung cancer (NSCLC),&#xa0;which comprises roughly 85% to 90% of all lung cancers</a>. NSCLC&#xa0;includes three different sub-types of lung cancer and can occur in people who smoke and people who don't.</p>
<div class="page" title="Page 2">
<div class="layoutArea">
<div class="column">
<p>When advanced, NSCLC is currently considered incurable.</p>
<p><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa011954">Less than 30%</a> of people with a form of NSCLC that has spread throughout the body respond to the most commonly used initial treatment in this stage of the disease, platinum-based chemotherapy. Even when other forms of treatment are added, <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa061884">the median life expectancy for patients with this type of NSCLC is one a year</a> after diagnosis. Just <a href="http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/Patient/page1">3.5% of patients survive 5 years</a>.</p>
<h2>Promising, but not a panacea</h2>
<p>Though promising, it's unlikely that the drug is going to cure or eliminate lung cancer anytime soon, since <a href="http://news.xinhuanet.com/english2010/health/2011-09/07/c_131111574.htm">it's designed to work by attacking a certain type of protein that cancer tumors produce rather than the cancer tumors themselves</a>.</p>
<p>As such, the drug helps take advantage of someone's existing immune response, coaxing the body into releasing a flood of antibodies to curb tumor growth. In some people, this treatment could have the capacity to transform lung cancer from an immediate death sentence into a long term, semi-manageable disease.</p>
<p>"With this kind of product, maybe cancer, advanced cancer, can be treated like any other chronic disease like diabetes," Center for Molecular Immunology scientist <a href="http://www.cnn.com/2009/HEALTH/02/19/cuba.cancer.vaccine/index.html?iref=24hours">Gisela Gonzales told Xinhua News back in 2011.</a></p>
</div>
</div>
</div>

Cuba has a revolutionary lung cancer treatment - and the US will likely get it soon

<p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"><p class="source"><span>Markets Insider</span></p></div><p></p></div></div><span></span></p><p>The competition over a new class of cancer drugs is heating up.</p><p><span>On Thursday, drugmaker Bristol</span>-Myers Squibb said that it wouldn't go for an accelerated US <span>approval </span>for a combination of its two immunotherapy drugs as an initial treatment for<span> lung </span><span>cancer - helping its rival, Merck pull ahead</span>.</p><p>Shares of<span> BMS were down 9% Friday morning on the news, while Merck was up 3.6%. </span></p><p>BMS cited "a review of data available at this time" for the decision to hold off on filing for Food and Drug Administration<span> approval </span>of the combination of its<span> cancer </span>drugs Opdivo and Yervoy.</p><p>Jefferies analyst Jeffrey Holford said in a research note that he still expects the<span> BMS </span>immunotherapy combination to be approved in the second half of 2018 and sees "no real change to valuation or estimates as a result of this update."</p><p>But the move helps secure Merck's current lead in the development of combination<span> lung </span><span>cancer </span>treatments. </p><p>Merck last week said U.S. regulators had agreed to an accelerated review of its application to combine immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced<span> lung </span><span>cancer</span>.</p><p>Merck said the FDA would decide by May 10 whether to approve its combination treatment.</p><h2>Why the combination cancer treatment is key</h2><p>Lung cancer is the second most common type of cancer, after <a href="http://www.businessinsider.com/deadliest-worst-cancers-2016-1">breast cancer, and it's one of the deadliest</a>.</p><p>Keytruda and Opdivo, which both block a protein called PD-1 to boost the ability of the body's own immune system to kill<span> cancer </span>cells, are already approved to treat a range of<span> cancer</span>s, but their biggest market would be first-line<span> lung </span><span>cancer</span>. Yervoy targets a different protein called CTLA-4.</p><p>Immunotherapy is revolutionizing some areas of<span> cancer </span>care but giving it on its own only seems to work better than chemotherapy in previously untreated<span> lung </span><span>cancer </span>patients who have high levels of a protein called PD-L1. Merck's Keytruda is already approved for such patients.</p><p>But not <a href="http://www.businessinsider.com/how-cancer-immunotherapy-works-2016-12">everybody responds to the PD-1 drugs</a>. Just a quarter to a third of non-small cell lung cancer (NSCLC) patients have tumors with at least 50 percent of cells producing PD-L1. That leaves about 70% of the market still up for grabs for combinations that could include chemotherapy or other forms of immunotherapy.</p><p>Jefferies' Holford said he still expects the front line, or initial, treatment of NSCLC patients to evolve toward combinations of immunotherapy drugs without chemotherapy, where <span>BMS </span>and AstraZeneca have super positions.</p><p><em>Reuters reporting by Deena Beasley.</em></p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/new-study-debunks-strongest-argument-against-global-warming-climate-change-2017-1">A new study just blew a hole in one of the strongest arguments against global warming</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="41cTV3ODE6lScG4haYqmvmNGCs1JhD5w" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

Bristol-Myers Squibb won't be going after a fast approval for its lung cancer drug

<p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"><p class="source"><span><a href="http://pictures.reuters.com/C.aspx?VP3=SearchResult&amp;VBID=2C0BXZGG1SZ74&amp;SMLS=1&amp;RW=1591&amp;RH=954#/SearchResult&amp;VBID=2C0BXZGG1SZ74&amp;SMLS=1&amp;RW=1591&amp;RH=954&amp;POPUPPN=3&amp;POPUPIID=2C0408TVXK6G2">REUTERS/Issei Kato</a></span></p><p class="caption">Takeda CEO Christophe Weber.</p></div><p></p></div></div>The Japanese pharmaceutical company Takeda is buying Cambridge, Massachussets-based ARIAD Pharmaceuticals for $24 a share.</p><p>The deal is valued at about $5.2 billion and expected to close in February.</p><p>"This is a very exciting time for Takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies," said Takeda CEO Christophe Weber in a statement.</p><p>"Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this transaction to benefit patients, our shareholders and other stakeholders."</p><p>Evercore advised Takeda, while JPMorgan, Goldman Sachs, and Lazard advised ARIAD.</p><p>Here's the press release:</p><p style="padding-left: 30px;">CAMBRIDGE, Mass. &amp; OSAKA, Japan--(<span><span><a href="http://www.businesswire.com/" rel="nofollow">BUSINESS WIRE</a></span></span>)--Takeda Pharmaceutical Company Limited (TSE:4502) ("Takeda") and ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) ("ARIAD") today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Sarissa Capital, the holder of 6.6% of ARIAD's common shares, as well as each of the members of ARIAD's Board of Directors have agreed to tender their shares to Takeda pursuant to the offer.</p><p style="padding-left: 30px;">"The acquisition of ARIAD is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders," said Christophe Weber, president and chief executive officer of Takeda. "This is a very exciting time for Takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies. Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this transaction to benefit patients, our shareholders and other stakeholders."</p><p style="padding-left: 30px;">Paris Panayiotopoulos, president and chief executive officer of ARIAD, said, "We are very pleased to combine with Takeda, which will allow us to not only accelerate our mission to discover, develop and deliver precision therapies to patients with rare cancers, but also deliver immediate and meaningful value to our shareholders through a substantial cash premium. This exciting transaction is a testament to the hard work and dedication of ARIAD's talented team of employees. We have tremendous respect for Takeda, and I believe our shared commitment to innovation and research-driven cultures will provide for a smooth transition."</p><p style="padding-left: 30px;">"This transaction is a great outcome for shareholders of ARIAD and Takeda. Both ARIAD and Takeda are passionate about helping cancer patients, and I believe the talent and resources of Takeda coupled with ARIAD's pipeline and people will accelerate the development of cancer treatments. I would like to extend my deepest gratitude to the management team and everyone at ARIAD for their unrelenting dedication," said Alexander J. Denner, Ph.D., Chairman of the Board of ARIAD.</p><p style="padding-left: 30px;"><strong>Highly strategic deal which transforms global oncology portfolio and pipeline by expanding into solid tumors and reinforcing existing strength in hematology</strong></p><p style="padding-left: 30px;">The acquisition of ARIAD brings two innovative targeted therapies that will expand and enhance Takeda's existing oncology portfolio. Brigatinib, an investigational drug product, has the potential to add a differentiated, global therapy in a genetically-defined subpopulation of non-small cell lung cancer (NSCLC). The addition of Iclusig will broaden Takeda's strong hematology franchise to include chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Together, these two innovative targeted therapies will position Takeda for sustainable long-term growth in oncology.</p><p style="padding-left: 30px;">Takeda's track record of successful oncology product launches [ADCETRIS<sup>®</sup> (Brentuximab Vedotin), NINLARO<sup>TM </sup>(ixazomib) and VELCADE<sup>®</sup> (bortezomib)] means it has the experience and expertise required to deliver the successful launch of brigatinib and to ensure that it achieves global reach and share of voice thereafter.</p><p style="padding-left: 30px;"><strong>Accretive to Takeda's Underlying Core Earnings by FY2018 and generates immediate and long-term revenue growth</strong></p><p style="padding-left: 30px;">The transaction is a compelling opportunity for Takeda shareholders. It will provide immediate revenue, bring considerable long-term revenue potential and deliver synergy savings.</p><p style="padding-left: 30px;">ARIAD provided calendar year 2016 revenue guidance for Iclusig of $170-180 million, and Takeda expects significant long-term revenue potential from the two lead assets.</p><p style="padding-left: 30px;">Takeda projects the acquisition of ARIAD to be accretive to Underlying Core Earnings by FY2018 and broadly neutral in FY2017. Strong revenue growth and synergy savings will offset increased sales and <keyword id="6354839" type="ORGANIZATION" weightage="60" keywordseo="marketing">marketing</keyword> costs for the brigatinib launch.</p><p style="padding-left: 30px;"><strong>Attractive value drivers include two very innovative medicines, Iclusig and brigatinib, an exciting early stage pipeline and cost synergies</strong></p><p style="padding-left: 30px;">Iclusig, a commercialized therapy with continued strong sales growth potential, delivers immediate value. Brigatinib, an investigational drug product with peak annual sales potential of over $1 billion, will generate significant long-term value for Takeda. U.S. approval is expected in the first half of 2017 with global filing thereafter. Beyond Iclusig and brigatinib, ARIAD's commitment and expertise in targeted kinase inhibition linked to strong translational <keyword id="41551" type="ENTERTAINMENT" weightage="60" keywordseo="science">science</keyword> generated further pipeline opportunities which provide additional long-term upside potential.</p><p style="padding-left: 30px;">Takeda will leverage ARIAD's R&amp;D capabilities and platform, and largely absorb its R&amp;D costs within Takeda's existing R&amp;D budget. G&amp;A cost synergies will be fully captured by FY2018.</p><p style="padding-left: 30px;"><strong>Takeda retains financial flexibility with no impact on dividend policy</strong></p><p style="padding-left: 30px;">The transaction will be funded by up to $4.0 billion of new debt and the remainder from existing cash. FY2017 Net Debt/EBITDA is estimated at approximately 2.6x, which is expected to remain investment grade. The transaction has no impact on Takeda's dividend policy.</p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/property-brothers-what-tricky-real-estate-code-words-really-mean-2016-12">The Property Brothers teach the actual meaning of tricky real estate 'code words'</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="pwMHIzMzE6ScSRLxmN5b0zjEe3_Nvmgy" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

Takeda is buying ARIAD Pharmaceuticals in a $5.2 billion deal

Chhath Puja 2024 Wishes

Bank holidays in India

ChatGPT will let you create images for free

Should the government give freebies to the poor?

World’s most powerful passports

Jio vs Airtel vs Vi Prepaid Plans

You Searched For "NSCLC" and got 5 results

Susan Wojcicki, YouTube CEO, died at 56 from a type of lung cancer that is often diagnosed late

Julia Pugachevsky

NovoCure surges 65% to all-time high on upbeat review of its lung cancer treatment trial

Isabelle Lee

Cuba has a revolutionary lung cancer treatment - and the US will likely get it soon

Erin Brodwin

Bristol-Myers Squibb won't be going after a fast approval for its lung cancer drug

Lydia Ramsey,Reuters

Takeda is buying ARIAD Pharmaceuticals in a $5.2 billion deal

Portia Crowe

Popular Keywords

Buying Guides